Suchergebnisse - "Xu, Xiaowei"

PubPharm (29)

1

Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma

enthalten in: Molecular cancer therapeutics | 2023

von Glasheen, M. | Caksa, S. | Young, A. | +8

2

Inactivation of the Hippo tumor suppressor pathway promotes melanoma

enthalten in: Nature communications | 2022

von Vittoria, M. | Kingston, N. | Kotynkova, K. | +12

3

Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

enthalten in: Nature communications | 2022

von Capparelli, C. | Purwin, T. | Glasheen, M. | +19

4

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

enthalten in: Oncogene | 2021

von Wang, B. | Zhang, W. | Zhang, G. | +19

5

Pathological response and survival with neoadjuvant therapy in melanoma : a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

enthalten in: Nature medicine | 2021

von Menzies, A. | Amaria, R. | Rozeman, E. | +20

CommentIn: Nat Rev Clin Oncol. 2021 Apr;18(4):193. - PMID 33627793

6

Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma

enthalten in: Molecular cell | 2020

von Webster, M. | Fane, M. | Alicea, G. | +29

ErratumIn: Mol Cell. 2020 Feb 6;77(3):681. - PMID 32032511

7

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

enthalten in: Cancer discovery | 2019

von Ojha, R. | Leli, N. | Onorati, A. | +25

ErratumIn: Cancer Discov. 2019 Jul;9(7):981. - PMID 31262747

8

NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib

enthalten in: Journal of cutaneous pathology | 2019

von Parekh, V. | Sobanko, J. | Miller, C. | +11

9

Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis

enthalten in: Nature communications | 2018

von Liu, S. | Zhang, G. | Guo, J. | +32

ErratumIn: Nat Commun. 2019 Mar 11;10(1):1211. - PMID 30858377

10

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Yam, C. | Xu, X. | Davies, M. | +18